PriceTargets.com logo

Omnicell - OMCL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $82.11
  • Forecasted Upside: 45.02%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$56.62 As of 02/7/2023 01:30 PM ET
▲ +1.24 (2.24%)

This chart shows the closing price for OMCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omnicell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMCL

Analyst Price Target is $82.11
▲ +45.02% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $82.11, with a high forecast of $157.00 and a low forecast of $54.00. The average price target represents a 45.02% upside from the last price of $56.62.

This chart shows the closing price for OMCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Omnicell. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2023KeyCorpLower TargetOverweight$75.00 ➝ $70.00Low
1/27/2023SVB LeerinkReiterated RatingMarket PerformLow
1/27/2023Piper SandlerBoost TargetOverweight$55.00 ➝ $66.00Low
1/24/2023Wells Fargo & CompanyLower TargetOverweight$71.00 ➝ $65.00Low
12/14/2022Piper SandlerLower Target$55.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetNeutral$140.00 ➝ $57.00Low
11/4/2022Wells Fargo & CompanyLower TargetOverweight$158.00 ➝ $71.00Low
11/3/2022Craig HallumLower Target$185.00 ➝ $75.00N/A
11/3/2022BenchmarkDowngradeBuy ➝ HoldN/A
11/3/2022BTIG ResearchLower TargetBuy$160.00 ➝ $75.00N/A
11/3/2022KeyCorpLower TargetOverweight$130.00 ➝ $75.00N/A
11/3/2022SVB LeerinkLower TargetMarket Perform$117.00 ➝ $54.00N/A
11/2/2022Piper SandlerLower Target$145.00 ➝ $58.00N/A
9/23/2022BenchmarkLower TargetBuy$170.00 ➝ $157.00Low
9/21/2022BTIG ResearchLower TargetBuy$175.00 ➝ $160.00Low
9/21/2022Piper SandlerLower TargetOverweight$150.00 ➝ $145.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$130.00Low
9/9/2022Bank of AmericaInitiated CoverageBuy$120.00Low
8/8/2022Piper SandlerLower TargetOverweight$162.00 ➝ $150.00Low
7/27/2022BTIG ResearchLower TargetBuy$190.00 ➝ $175.00Low
7/15/2022SVB LeerinkInitiated CoverageMarket Perform ➝ Market Perform$124.00Low
5/3/2022Wells Fargo & CompanyLower TargetOverweight$188.00 ➝ $158.00Low
5/2/2022Piper SandlerLower Target$181.00 ➝ $162.00Low
2/16/2022Wells Fargo & CompanyLower TargetOverweight$203.00 ➝ $188.00High
12/6/2021Wells Fargo & CompanyInitiated CoverageOverweight$203.00High
12/1/2021BTIG ResearchBoost TargetPositive ➝ Buy$210.00 ➝ $220.00Low
11/3/2021Craig HallumBoost TargetBuy$170.00 ➝ $205.00Low
11/3/2021Piper SandlerBoost TargetOverweight$188.00 ➝ $211.00Low
10/26/2021BTIG ResearchBoost TargetPositive ➝ Buy$175.00 ➝ $200.00High
7/27/2021BTIG ResearchReiterated RatingBuy$165.00 ➝ $151.49Low
6/23/2021Piper SandlerBoost TargetOverweight$152.00 ➝ $188.00Low
6/9/2021JPMorgan Chase & Co.Initiated CoverageNeutral$146.00Low
5/24/2021BTIG ResearchInitiated CoverageBuy$165.00Low
4/30/2021BenchmarkBoost TargetBuy$155.00 ➝ $160.00Low
4/30/2021Piper SandlerBoost TargetOverweight$147.00 ➝ $152.00Medium
3/22/2021BenchmarkBoost TargetBuy$140.00 ➝ $155.00Low
2/2/2021Piper SandlerUpgradeNeutral ➝ Overweight$86.00 ➝ $147.00N/A
1/20/2021BenchmarkBoost TargetBuy$125.00 ➝ $140.00Low
1/14/2021Craig HallumBoost TargetBuy$100.00 ➝ $142.00Low
12/9/2020BenchmarkBoost TargetBuy$100.00 ➝ $125.00High
12/8/2020Berenberg BankInitiated CoverageBuyHigh
12/3/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$95.00High
10/28/2020Craig HallumBoost TargetBuy$85.00 ➝ $100.00High
10/28/2020Wells Fargo & CompanyBoost TargetEqual Weight$74.00 ➝ $84.00Low
10/28/2020BenchmarkBoost TargetBuy$82.00 ➝ $100.00Low
10/28/2020Cantor FitzgeraldBoost TargetOverweight$90.00 ➝ $95.00Low
10/28/2020Piper SandlerBoost TargetNeutral$70.00 ➝ $86.00Low
7/29/2020Craig HallumLower TargetBuy$102.00 ➝ $85.00Medium
7/29/2020Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $90.00High
7/29/2020Piper SandlerLower TargetNeutral$76.00 ➝ $70.00High
7/6/2020StephensInitiated CoverageOverweight$90.00Medium
5/8/2020BenchmarkLower TargetBuy$96.00 ➝ $82.00High
5/8/2020Cantor FitzgeraldLower TargetOverweight$95.00 ➝ $85.00High
5/8/2020Piper SandlerLower TargetNeutral$88.00 ➝ $76.00High
2/7/2020Piper SandlerReiterated RatingHold$88.00Medium
2/7/2020Dougherty & CoBoost TargetBuy$92.00 ➝ $100.00High
1/8/2020Wells Fargo & CompanyBoost TargetEqual Weight$80.00 ➝ $85.00Low
12/11/2019Cantor FitzgeraldReiterated RatingOverweight$91.00 ➝ $95.00Low
11/21/2019Dougherty & CoBoost TargetBuy$90.00 ➝ $92.00Medium
10/25/2019SidotiSet TargetHold$82.00N/A
7/26/2019Craig HallumUpgradeHold ➝ Buy$85.00Low
4/26/2019BenchmarkBoost TargetBuy$82.00 ➝ $90.00Low
4/26/2019Craig HallumDowngradeBuy ➝ Hold$84.00Low
3/7/2019Dougherty & CoBoost TargetBuy$78.00 ➝ $90.00Low
2/8/2019Piper Jaffray CompaniesReiterated RatingNeutral$70.00High
12/7/2018OppenheimerBoost TargetOutperform$86.00Low
12/6/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $80.00Low
10/29/2018Wells Fargo & CompanyBoost TargetMarket Perform ➝ Market Perform$59.00 ➝ $61.00Medium
10/26/2018OppenheimerBoost TargetOutperform ➝ Outperform$71.00 ➝ $73.00N/A
10/26/2018Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$63.00 ➝ $70.00High
10/5/2018BenchmarkBoost TargetBuy$66.00 ➝ $79.00Low
9/17/2018Craig HallumBoost TargetBuy$65.00 ➝ $80.00Medium
7/27/2018Piper Jaffray CompaniesBoost TargetNeutral ➝ Neutral$44.00 ➝ $55.00High
7/27/2018Craig HallumUpgradeHold ➝ Buy$33.00High
7/26/2018Cantor FitzgeraldReiterated RatingBuy$63.00High
6/29/2018BenchmarkInitiated CoverageBuy ➝ Buy$63.00Low
4/3/2018Cantor FitzgeraldReiterated RatingBuy$63.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
7/12/2022
  • 1 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/10/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/9/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
1/8/2023
  • 9 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 9 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Omnicell logo
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.
Read More

Today's Range

Now: $56.62
Low: $54.52
High: $56.62

50 Day Range

MA: $52.13
Low: $46.90
High: $60.43

52 Week Range

Now: $56.62
Low: $46.11
High: $159.57

Volume

77,531 shs

Average Volume

451,173 shs

Market Capitalization

$2.51 billion

P/E Ratio

55.51

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Omnicell?

The following Wall Street sell-side analysts have issued stock ratings on Omnicell in the last year: Bank of America Co., Benchmark Co., BTIG Research, Craig Hallum, JPMorgan Chase & Co., KeyCorp, Piper Sandler, StockNews.com, SVB Leerink LLC, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for OMCL.

What is the current price target for Omnicell?

9 Wall Street analysts have set twelve-month price targets for Omnicell in the last year. Their average twelve-month price target is $82.11, suggesting a possible upside of 45.0%. Benchmark Co. has the highest price target set, predicting OMCL will reach $157.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $54.00 for Omnicell in the next year.
View the latest price targets for OMCL.

What is the current consensus analyst rating for Omnicell?

Omnicell currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMCL will outperform the market and that investors should add to their positions of Omnicell.
View the latest ratings for OMCL.

What other companies compete with Omnicell?

Other companies that are similar to Omnicell include Agiliti, Corcept Therapeutics, Pacific Biosciences of California, Prothena and Xenon Pharmaceuticals. Learn More about companies similar to Omnicell.

How do I contact Omnicell's investor relations team?

Omnicell's physical mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is (650) 251-6100 and its investor relations email address is [email protected] The official website for Omnicell is www.omnicell.com. Learn More about contacing Omnicell investor relations.